[Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
Hosokawa
Ayumu
A
Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East.
D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069287:Capecitabine; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000556:secondary*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004338:Drug Combinations; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous; D010094:Oxonic Acid / Q000008:administration & dosage; D011379:Prognosis; D011725:Pyridines / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D013940:Thymidylate Synthase / Q000378:metabolism; D014498:Uracil / Q000008:administration & dosage
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D014498:Uracil; D010094:Oxonic Acid; D000069287:Capecitabine; D013940:Thymidylate Synthase; D005472:Fluorouracil